James W. Murrough, MD, PhD

Icahn School of Medicine at Mount Sinai, New York, New York; VISN 2 Mental Illness Research, Education, and Clinical Center (MIRECC), James J. Peters VA Medical Center, Bronx, New York

  • 9Articles
  • 71KReads
  • 2011–2025Active
  • 57Collaborators
  • 400Citations

About

James W. Murrough, MD, PhD, is affiliated with the Icahn School of Medicine at Mount Sinai and the VISN 2 Mental Illness Research, Education, and Clinical Center at the James J. Peters VA Medical Center. His publications from 2011 to 2025 focus on major depressive disorder, posttraumatic stress disorder, and electroconvulsive therapy. His research topics include the cognitive effects of ketamine and electroconvulsive therapy, rapid symptom improvement with esketamine, and the integration of novel antidepressants. He has collaborated frequently with co-authors such as Sanjay J. Mathew and Dennis S. Charney.

Publications

JCP
Comparing the Cognitive Effects of Repeated IV Ketamine and ECT in Patients with Treatment-Resistant Depression: A Secondary Analysis of the ELEKT-D Trial
Original Research

Comparing the Cognitive Effects of Repeated IV Ketamine and ECT in Patients with Treatment-Resistant Depression: A Secondary Analysis of the ELEKT-D Trial

September 3, 2025

Patients treated with ketamine demonstrated superior cognitive functioning compared with those treated with ECT following a 3-week treatment course. No differences between treatments were observed among responders in at...
, , , et al
JCP
Ketamine Infusions and Written Exposure Therapy for Chronic PTSD
Original Research

Ketamine Infusions and Written Exposure Therapy for Chronic PTSD

April 2, 2025

Preliminary findings suggest that the combined treatment may yield large and durable symptom reductions for patients with severe chronic PTSD
, , , et al
JCP
Rapidity of Improvement With Intranasal Esketamine for MDD
Meta-Analysis

Rapidity of Improvement With Intranasal Esketamine for MDD

December 12, 2022

This meta-analysis found that augmenting antidepressants with intranasal esketamine vs placebo was more effective in reducing depression severity at 24 hours and study endpoint.
, , , et al
JCP
Meta-Analysis

Vortioxetine for Major Depressive Disorder

June 15, 2021

Prior meta-analyses have found vortioxetine to be efficacious for depression. Building on those findings, the present meta-analysis examined the effect that placebo response has on drug-placebo effect size in...
, , , et al
JCP
Original Research

Symptoms, Burnout, and Functioning in HCWs During COVID-19

April 27, 2021

The pandemic has clearly placed a tremendous strain on health care workers, but how has it affected their ability to function in their daily lives and the likelihood of...
, , , et al
JCP
Meta-Analysis

Esketamine Augmentation in Major Depressive Disorder

May 26, 2020

The FDA has now approved intranasal esketamine as augmention in treatment-resistant depression, and recent studies of its efficacy have been encouraging. This meta-analysis synthesizes the evidence to provide an...
, , , et al
JCP
Educational Activity

Integrating Novel Antidepressants in MDD Treatment

July 30, 2019

New mechanisms of action present new opportunities to improve outcomes for patients with depression. Listen to a panel of experts discuss best practices and novel antidepressants at the 2019...
, , , et al
JCP
Original Research

Ketamine Safety and Tolerability in Clinical Trials for Treatment-Resistant Depression

September 2, 2014

, , , et al
JCP
Letter to the Editor

A Case of Sustained Remission Following an Acute Course of Ketamine in Treatment-Resistant Depression

March 15, 2011

, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe